GENinCode plc (AIM: GENI) has conditionally raised £3.9m in gross proceeds through the issue of 388,145,000 new ordinary shares at 1p each, representing a 47.4pc discount to the closing middle
GENinCode plc (AIM: GENI) has conditionally raised £3.9m in gross proceeds through the issue of 388,145,000 new ordinary shares at 1p each, representing a 47.4pc discount to the closing middle
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
FTSE 100 ends session near all-time peak, closing up 59.65 points at 9,897, a gain of 0.6% that leaves the index edging closer to its record high of 9,930 set
GENinCode Plc has entered into a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, which is designed to help predict and prevent
The Times: The headline rate of inflation fell more than expected in November to a 10-month low – increasing expectations that the Bank of England will cut interest rates tomorrow. The
Amazing AI plc (AQSE: AAI) AAI is a global fintech group with a Digital Asset Treasury Policy that provides online consumer loans and AI finance-related services. AAI announces that a circular
GENinCode Plc (AIM: GENI) shares climbed 33% after the company announced a major collaboration with Thermo Fisher Scientific to commercialise its CARDIO inCode-Score® Polygenic Risk Score test for predicting and
GENinCode PLC (AIM: GENI) jumped 32% to 2.84p in early trading after securing approval from the New York State Department of Health (NYSDOH) for its CARDIO inCode-Score test, which assesses
Solvonis Therapeutics plc (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, announced that its novel AI-discovered compound, SVN-015, targeting methamphetamine and cocaine use disorders,
The Telegraph: Co-op unveils £206m hit from cyber attack. IT shutdown led to data from retailers’ 6.5 million members being stolen
GENinCode plc (AIM: GENI.L), a genetics company focused on the prevention of cardiovascular disease (“CVD”) and the early detection of ovarian cancer, announced on 14 February 2025 the launch of a fundraising comprising a